14th Mar 2025 07:00
LEI: 549300Q7EXQQH6KF7Z84
14 March 2025
RTW Biotech Opportunities Ltd
Monthly Valuation Update and Factsheet
-5.0% NAV movement for the month
RTW Biotech Opportunities Ltd (the "Company") announces that the unaudited net asset value attributable to the ordinary shares of the Company at the close of business on 28 February 2025 (the "NAV") was US$601.5 million, or US$1.79 per ordinary share, -5.0% from the previous month.
The monthly factsheet is available on the Company's website:
https://www.rtwfunds.com/rtw-biotech-opportunities-ltd/factsheets-letters/
Enquiries:
RTW Investments, LP - Investment Manager Woody Stileman (Business Development) Oliver Kenyon (Business & Corporate Development) Krisha McCune (Investor Relations)
| +44 (0)20 7959 6361 |
Cadarn Capital - PR & IR Partner Lucy Clark (PR) David Harris (Distribution) |
+44 (0)7984 184 461 / [email protected] +44 (0)7368 883 211 / [email protected]
|
Deutsche Numis - Joint Corporate Broker Freddie Barnfield Nathan Brown Euan Brown
| +44 (0)20 7260 1000 |
BofA Securities - Joint Corporate Broker Edward Peel Alex Penney
| +44 (0)20 7628 1000 |
Altum (Guernsey) Limited Joanna Duquemin Nicolle Sadie Morrison
| +44 (0)1481 703 100 |
About Biotech Opportunities Ltd:
RTW Biotech Opportunities Ltd (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Biotech Opportunities Ltd invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.
Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd for more information.
***********
The information in this announcement may include forward-looking statements, which are based on the current expectations and projections about future events, and in certain cases can be identified by the use of terms such as "may", "will", "should", "expect", "anticipate", "project", "estimate", "intend", "continue", "target", "believe" (or the negatives thereon) or other variations thereon or comparable terminology. These forward-looking statements, as well as those included in any related materials, are subject to risks, uncertainties and assumptions about the Company and/or its underlying investments, including, among other things, the development of the applicable entity's business, trends in its operating industry, expected use of financing proceeds and future capital expenditures and acquisitions. In light of these risks, uncertainties and assumptions, the events in the forward-looking statements may not occur.
The information contained in this announcement is given at the date of its publication (unless otherwise marked). No reliance may be placed for any purpose whatsoever on the information or opinions contained in this announcement or on its completeness, accuracy or fairness.
***********
Related Shares:
Rtw Biotech